Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antib...

Full description

Bibliographic Details

Published in:	IJTLD Open
Main Authors:	L. Kuksa, C. Andrejak, B. Haecker, G. Bothamley, A. Calcagno, D.M. Cirillo, R. Duarte, R. Fatima, G. Ferlazzo, L. Guglielmetti, G. Günther, C. Hewison, C.R. Horsburgh, T. Jäger, Y. Kalancha, R. Otto-Knapp, K. Kranzer, T. Lillebaek, G. Marks, K. Middelkoop, I. Motta, V. Rabinova, P. Sommerfeld, P. Tattevin, C. Lange
Format:	Article
Language:	English
Published:	International Union Against Tuberculosis and Lung Disease (The Union) 2025-03-01
Subjects:	tuberculosis drug resistance mdr-tb rr-tb xdr-tb european medicines agency
Online Access:	https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000003/art00001